We are pleased to welcome Teena Chopra, MD, MPH, Clinician Educator as a Member of the C Diff Foundation, Co.-Director of the Junior Infection Fighter Program – Infection Prevention Education.
Dr. Chopra is a Professor of Medicine in the Division of Infectious Diseases, at Wayne State University and the Corporate Medical Director of Hospital Epidemiology, Infection Prevention and Antibiotic Stewardship at Detroit Medical Center, Wayne State University. Her research interests include Epidemiology of Healthcare-associated Infections, Infection Prevention Antibiotic Stewardship and Immunization.
Dr. Chopra has published over 70 papers in various journals and book chapters. Additionally she has independently reviewed over 50 journal articles, and has a special interest in studying the epidemiology of infections, including Clostridium difficile and Multi-Drug Resistant Organisms.
Thanksgiving is that time of year with expressions of gratitude and thankfulness for those in our lives. For some people, it’s extremely difficult and maybe even a bit complicated and we understand. For others, it’s a time for harvesting the strength to push forward and allow more time for healing and we understand. It’s a day in the journey where we pause to share the attitude of gratitude for the little things in life. On behalf of all the members, patient advocates, and the C Diff Foundation family worldwide, we send you and your family our warmest wishes, Happy Thanksgiving.
C Diff Foundation Board presented Rebiotix CEO Lee Jones for Advocacy, Innovation in C. difficile infection treatment
(NEW PORT RICHEY, Fla.) — The C. Diff Foundation Board of Directors announced that the 2019 “Above and Beyond” Award was presented to Rebiotix CEO Lee Jones in Roseville, Minnesota. The award, given to one recipient annually, is given to a person or organization that show extraordinary dedication to C. diff. patient safety, advocacy, and overall drive to improve the lives of those impacted by the infection.
“We are very proud to recognize Ms. Jones with our “Above and Beyond” award,” said C. Diff Foundation Founder and President, Nancy Caralla. “Lee’s dedication to the entire C.diff. community of patients, family members, and physicians hasn’t wavered since the founding of Rebiotix in 2011. She is a true example of what can happen when focusing on patient well-being drives new approaches to healthcare.”
The award was presented by the Foundation’s Vice President, Scott Battles at the Rebiotix office.
“It’s an honor to receive this award from the C. Diff Foundation,” said Ms. Jones. “The purpose of starting Rebiotix was to bring the power of the microbiome to the clinic in a scientifically sound, quality-controlled way to help patients. We stand with the Foundation in believing that patient well-being should be at the core of all that we do, from clinical trials to exploring new scientific landscapes within the microbiome space.”
About Rebiotix Inc.:
Rebiotix Inc., part of the Ferring Pharmaceuticals Group, is a late-stage clinical microbiome company focused on harnessing the power of the human microbiome to revolutionize the treatment of debilitating diseases. Rebiotix possesses a deep and diverse clinical pipeline, with its lead drug candidate, RBX2660, in Phase 3 clinical development for the prevention of recurrent Clostridium difficile (C. diff) infection. RBX2660 has been granted Fast Track, Orphan and Breakthrough Therapy designation from the FDA for its potential to prevent recurrent C. diff infection.
Rebiotix’s clinical pipeline also features RBX7455, a lyophilized, room temperature stable oral capsule formulation. Rebiotix is also targeting several other disease states with drug products built on its pioneering Microbiota Restoration Therapy(tm) platform. For more information on Rebiotix and its pipeline of human microbiome-directed therapies, visit https://www.rebiotix.com/